PURE Bioscience, Inc. ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2024.
Summary of Results ? Fiscal.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On June 12, 2024, Yield10 Bioscience, Inc. filed a Certificate of Amendment to its Amended.
Population growth or size is an essential component of economic development. A robust and vibrant population allows countries to allocate more labor to industrial and other economic activities.
Daré Bioscience, Inc. (NASDAQ:DARE) Short Interest Update modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ SN Bioscience Co., Ltd. (CEO Park Young-hwan) announced on May 24 that European Medicines Agency(EMA) had granted an orphan drug designation.